SCE-Medical-Oncology Medical Oncology (Specialty Certificate Examination) — Exam Overview
Quick Facts
SCE-Medical-Oncology — Specialty Certificate Examination in Medical Oncology — is one of the 11 Specialty Certificate Examinations in the MRCP(UK) programme run by the Federation of the Royal Colleges of Physicians of the UK. Like every SCE it is examined with two 3-hour papers of 100 best-of-five questions (200 questions in total), delivered as in-centre computer-based testing, with one mark per correct answer, no negative marking and a maximum of six attempts; pass standards are equated per specialty and there is no fixed percentage pass mark. Its verbatim owner blueprint distributes the 200 questions across 27 areas: Breast cancer 14; Colorectal and anal cancer 14; Lung and thoracic cancer 14; Carcinoma of unknown origin 7; Ovarian cancer 7; Germ cell tumours 7; Oesophagogastric cancer 6; Lymphoma 3; Uterine cancer 3; Hepatobiliary cancer 5; Skin cancer 5; Sarcoma 5; Leukaemia 1; Prostate cancer 3; Urothelial cancer 3; Cervical cancer 3; Head and neck cancer 2; CNS cancer 2; Renal cell cancer 3; Endocrine cancer 2; Scientific basis of malignancy 18; Professional skills 14; Acute oncology 20; Clinical research, ethics and economics 8; Systemic anticancer therapy 18; Supportive therapies and palliative care 10; Standard operating procedures 3. This Study4Pass practice bank contains 80 original practice questions aligned to that blueprint. Quota note: Leukaemia carries an owner count of 1/200, which under the bank rule (owner count x 0.4, largest-remainder rounding to exactly 80) rounds to 0 questions; the topic is retained in the domain list with its verbatim owner weight.
Who this exam is for
Doctors in medical oncology specialty training, and physicians who deliver systemic anticancer therapy, who are preparing for the MRCP(UK) Specialty Certificate Examination in Medical Oncology.
Exam Domains
Breast cancer — 14/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering early breast cancer adjuvant therapy; HER2-positive disease; endocrine therapy; metastatic treatment sequencing.
Colorectal and anal cancer — 14/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering adjuvant chemotherapy; RAS and BRAF testing; metastatic sequencing; anal cancer chemoradiation.
Lung and thoracic cancer — 14/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering eGFR, ALK and PD-L1 testing; small cell lung cancer; mesothelioma; immunotherapy.
Carcinoma of unknown origin — 7/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering favourable and unfavourable subsets; immunohistochemistry; molecular profiling.
Ovarian cancer — 7/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering first-line chemotherapy; PARP inhibitors and BRCA; platinum sensitivity.
Germ cell tumours — 7/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering risk stratification; BEP chemotherapy; tumour markers AFP, hCG and LDH; surveillance.
Oesophagogastric cancer — 6/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering perioperative chemotherapy; HER2 testing; metastatic treatment.
Lymphoma — 3/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering hodgkin lymphoma; diffuse large B-cell lymphoma; ABVD and R-CHOP.
Uterine cancer — 3/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering endometrial cancer staging and adjuvant therapy; mismatch repair testing.
Hepatobiliary cancer — 5/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering hepatocellular carcinoma; cholangiocarcinoma; pancreaticobiliary supportive care.
Skin cancer — 5/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering melanoma adjuvant therapy; BRAF/MEK inhibition; basal cell carcinoma.
Sarcoma — 5/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering soft tissue sarcoma chemotherapy; GIST and imatinib; bone sarcomas.
Leukaemia — 1/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering acute leukaemia presentation and referral; tumour lysis risk.
Prostate cancer — 3/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering androgen deprivation; androgen receptor pathway inhibitors; metastatic hormone-sensitive disease.
Urothelial cancer — 3/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering cisplatin eligibility; perioperative chemotherapy; immunotherapy.
Cervical cancer — 3/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering chemoradiation; HPV and screening; recurrent disease.
Head and neck cancer — 2/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering hPV-positive oropharyngeal cancer; chemoradiation; EGFR inhibition.
CNS cancer — 2/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering glioblastoma chemoradiation; primary CNS lymphoma; brain metastases.
Renal cell cancer — 3/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering risk stratification; VEGF and immunotherapy combinations.
Endocrine cancer — 2/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering thyroid cancer; adrenocortical carcinoma; neuroendocrine tumours.
Scientific basis of malignancy — 18/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering hallmarks of cancer; oncogenes and tumour suppressors; DNA repair; angiogenesis; immune evasion; carcinogenesis.
Professional skills — 14/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering breaking bad news; consent for chemotherapy; multidisciplinary team working; communication with patients and families.
Acute oncology — 20/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering neutropenic sepsis; tumour lysis syndrome; spinal cord compression; hypercalcaemia; superior vena cava obstruction; immunotherapy toxicities.
Clinical research, ethics and economics — 8/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering trial phases; endpoints; consent and ethics; health economics and QALYs.
Systemic anticancer therapy — 18/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering cytotoxic mechanisms and toxicities; targeted therapy; immunotherapy; endocrine therapy; dose calculation and organ dysfunction.
Supportive therapies and palliative care — 10/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering antiemetics; pain control; malignant effusions; bone-modifying agents; end-of-life care.
Standard operating procedures — 3/200
One of the 27 areas in the verbatim owner blueprint for the Medical Oncology (Specialty Certificate Examination) (Federation of the Royal Colleges of Physicians of the UK blueprint PDF), covering chemotherapy prescribing and checking; extravasation; governance and incident reporting.
Preparing for SCE-Medical-Oncology
Work through the practice questions in study mode first, read every explanation, then switch to timed practice. Weight your revision by the domain weightings above and revisit the topics you score lowest on until your practice scores are consistent.
Write Your Review on SCE-Medical-Oncology Medical Oncology (Specialty Certificate Examination)
SCE-Medical-Oncology Customer Reviews
No reviews yet
Be the first to share your experience with this exam.